Published in World J Gastroenterol on March 01, 2004
Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev (2008) 1.88
Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? World J Gastroenterol (2006) 1.35
Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology (2012) 1.20
Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol (2005) 1.08
Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J Inflamm (Lond) (2005) 1.07
Campylobacter jejuni-induced cytokine responses in avian cells. Infect Immun (2005) 1.04
A C-type lectin MGL1/CD301a plays an anti-inflammatory role in murine experimental colitis. Am J Pathol (2008) 1.03
Pathologic patterns of interleukin 10 expression--a review. Biochem Med (Zagreb) (2015) 0.97
Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family. Mediators Inflamm (2015) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS One (2012) 0.95
Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm (2006) 0.89
Carrageenan-induced colonic inflammation is reduced in Bcl10 null mice and increased in IL-10-deficient mice. Mediators Inflamm (2013) 0.88
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J Gastroenterol (2012) 0.85
IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis. J Clin Immunol (2012) 0.84
Do we really understand what the immunological disturbances in inflammatory bowel disease mean? World J Gastroenterol (2009) 0.84
Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis. BMC Gastroenterol (2013) 0.84
Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm (2011) 0.84
Interleukin-10 repletion suppresses pro-inflammatory cytokines and decreases liver pathology without altering viral replication in murine cytomegalovirus (MCMV)-infected IL-10 knockout mice. Inflamm Res (2010) 0.83
Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol (2014) 0.83
Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther (2014) 0.82
Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. Dig Dis Sci (2007) 0.81
Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells. Mediators Inflamm (2015) 0.79
Interleukin-10 haplotypes in Celiac Disease in the Spanish population. BMC Med Genet (2006) 0.79
Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma. Int J Med Sci (2014) 0.79
Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials (2015) 0.79
Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4/NF-kB signaling pathway. Inflammopharmacology (2016) 0.78
A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease. Inflamm Bowel Dis (2013) 0.78
Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10. Lab Invest (2015) 0.77
Pathway-Based Genome-Wide Association Studies for Plasma Triglycerides in Obese Females and Normal-Weight Controls. PLoS One (2015) 0.77
Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. World J Gastroenterol (2006) 0.76
Angelica acutiloba Kitagawa Extract Attenuates DSS-Induced Murine Colitis. Mediators Inflamm (2016) 0.75
Expression of Tim-1 in primary CNS lymphoma. Cancer Med (2016) 0.75
The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel disease. Nutrients (2014) 0.75
Swimming attenuates inflammation, oxidative stress, and apoptosis in a rat model of dextran sulfate sodium-induced chronic colitis. Oncotarget (2016) 0.75
Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin. BMC Biotechnol (2007) 0.75
The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol (2016) 0.75
The S-layer Associated Serine Protease Homolog PrtX Impacts Cell Surface-Mediated Microbe-Host Interactions of Lactobacillus acidophilus NCFM. Front Microbiol (2017) 0.75
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 6.19
Control of intestinal inflammation by regulatory T cells. Immunol Rev (2001) 4.73
Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 3.21
Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene (1995) 3.09
Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol (2003) 2.87
Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol (2000) 2.71
The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res (1999) 2.66
Biologic therapy of inflammatory bowel disease. Gastroenterology (2002) 2.49
Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 2.45
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2000) 2.16
Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol (2003) 2.10
Regulatory T cells and inflammatory bowel disease. Immunol Today (1999) 1.94
Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem (1999) 1.77
Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun (2000) 1.58
Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 1.56
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Interleukin 10 gene transfer prevents experimental colitis in rats. Gut (2000) 1.38
Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology (2002) 1.35
Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol (1999) 1.24
Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol (2000) 1.24
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 1.15
Role of IL-10 for induction of anemia during inflammation. J Immunol (2002) 1.13
New treatments for inflammatory bowel disease. World J Gastroenterol (1998) 1.09
Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res (1999) 1.06
Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids. Br J Pharmacol (1999) 1.05
Current medical therapy of inflammatory bowel disease. World J Gastroenterol (2000) 1.00
Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol (1999) 0.98
Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut (2002) 0.95
TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J Immunol (2000) 0.94
IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut (2002) 0.91
Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion (2001) 0.91
Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease? Aliment Pharmacol Ther (2001) 0.89
Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut (1999) 0.86
IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes. Clin Exp Immunol (2000) 0.85
Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action. Biochem Biophys Res Commun (2000) 0.85
Transfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1. BMC Gastroenterol (2003) 0.84
New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther (2002) 0.83
Combining T cells and IL-10: a new therapy for Crohn's disease? Gastroenterology (2002) 0.83
Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy. Gastroenterology (2000) 0.82
Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin Immunol (2002) 0.80
Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J Gastroenterol (2003) 0.80
Germ therapy with IL-10 to treat inflammatory bowel diseases. Mol Med Today (2000) 0.77
Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis. J Gastroenterol (2002) 0.77
Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model. J Allergy Clin Immunol (2008) 1.34
Mast cells play a crucial role in Staphylococcus aureus peptidoglycan-induced diarrhea. Am J Pathol (2007) 1.06
Staphylococcal enterotoxin B increases TIM4 expression in human dendritic cells that drives naïve CD4 T cells to differentiate into Th2 cells. Mol Immunol (2007) 1.03
Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. BMC Microbiol (2006) 1.01
Induction of inflammatory cytokine release from human umbilical vein endothelial cells by agonists of proteinase-activated receptor-2. Clin Exp Pharmacol Physiol (2008) 0.93
Purification, characterization and potent lung lesion activity of an L-amino acid oxidase from Agkistrodon blomhoffii ussurensis snake venom. Toxicon (2007) 0.89
Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol (2005) 0.89
Modulation of expression and function of Toll-like receptor 3 in A549 and H292 cells by histamine. Mol Immunol (2006) 0.88
Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: the role of TLR2 and NOD2. Immunol Cell Biol (2007) 0.86
IFN-λ inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production. Antiviral Res (2012) 0.85
Induction of mast cell accumulation, histamine release and skin edema by N49 phospholipase A2. BMC Immunol (2009) 0.84
Investigation into the signal transduction pathway via which heat stress impairs intestinal epithelial barrier function. J Gastroenterol Hepatol (2007) 0.83
Purification, characterization and biological activities of the L-amino acid oxidase from Bungarus fasciatus snake venom. Toxicon (2009) 0.83
Rhinosinusitis derived Staphylococcal enterotoxin B plays a possible role in pathogenesis of food allergy. BMC Gastroenterol (2006) 0.82
Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin (2006) 0.82
Unusual life-threatening Rosai-Dorfman disease of the trachea: role of NF-κB. Thorax (2010) 0.81
Expression of integrin alphavbeta6 in the intestinal epithelial cells of patients with inflammatory bowel disease. N Am J Med Sci (2009) 0.80
N49 phospholipase A2, a unique subgroup of snake venom group II phospholipase A2. Biochim Biophys Acta (2005) 0.80
Glucuronoxylomannan promotes the generation of antigen-specific T regulatory cell that suppresses the antigen-specific Th2 response upon activation. J Cell Mol Med (2009) 0.80
Potent histamine-releasing activity of atrahagin, a novel snake venom metalloproteinase. Int J Biochem Cell Biol (2005) 0.80
Induction of microvascular leakage and histamine release by promutoxin, an Arg49 phospholipase A2. Toxicon (2009) 0.79
Induction of inflammatory cell accumulation by TM-N49 and promutoxin, two novel phospholipase A(2). Toxicon (2010) 0.78
Purification, characterization and cytokine release function of a novel Arg-49 phospholipase A(2) from the venom of Protobothrops mucrosquamatus. Biochimie (2006) 0.78
The key role for local base order in the generation of multiple forms of China HIV-1 B'/C intersubtype recombinants. BMC Evol Biol (2005) 0.77
Evaluation of FORS-D analysis: a comparison with the statistically significant stem-loop potential. Biochem Genet (2007) 0.77
Plant allergic proteins and their biological functions. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) (2003) 0.76
Cloning and expression of human colon mast cell carboxypeptidase. World J Gastroenterol (2004) 0.76
Bridging PCR and partially overlapping primers for novel allergen gene cloning and expression insert decoration. World J Gastroenterol (2004) 0.75
A unique life-threatening mediastinal liposarcoma mimicking pleural effusion. Am J Respir Crit Care Med (2012) 0.75
Targeted NF-kappaB inhibition of asthmatic serum-mediated human monocyte-derived dendritic cell differentiation in a transendothelial trafficking model. Cell Immunol (2009) 0.75
[Eosinophil specific active markers in allergy]. Zhonghua Er Ke Za Zhi (2004) 0.75
[Prokaryotic expression of human mast cell chymase gene and preparation of its polyclonal antibody]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2007) 0.75
[Expression of LRG-1 in clinical specimens and Tca8113 cell line of tongue carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao (2016) 0.75